Herombopag for low platelets from chemotherapy side effects
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This Phase 2 trial studies herombopag to raise very low platelet counts caused by chemotherapy and reduce bleeding risk. It may help people whose platelet levels stay too low even after prior standard attempts like rhTPO or IL-11.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 years or older and able to follow study visits and procedures
- Have chemotherapy-induced low platelets (CIT) that did not improve after repeated treatment with rhTPO or IL-11
- Stop chemotherapy or radiotherapy for more than 1 month, and have platelet counts under 30 with a bleeding tendency
- Have enough health to stay in the study: liver and kidney tests must be below 1.5 times the normal limit, and expected survival is at least 6 months
- Not be pregnant or breastfeeding, and be willing to use reliable birth control during the study (with a negative pregnancy test for women)
- Most important to avoid: serious uncontrolled organ disease, life-threatening bleeding in the brain/lungs/upper stomach, major clotting conditions, and positive blood tests for HIV or hepatitis B/C/D or certain virus DNA tests
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests eltrombopag to help people with low platelet counts caused by chemotherapy (which can increase bleeding risk). It looks at whether raising platelets can reduce bleeding problems and help you stay on track with care.
This trial tests a medication called Herombopag to raise platelet counts in adults aged 60 or older with immune thrombocytopenia (ITP). The goal is to see if it is safe and effective for this age group.
This trial tests a drug called romiplostim for patients whose platelet counts stay very low (below 30) for a long time after chemotherapy, even after other treatments have failed. The goal is to see if romiplostim can help raise your platelet count to a safer level.
This study tests a medication called hetrombopag, which helps raise platelet counts. It's for people with acute myeloid leukemia who have low platelets after intensive chemotherapy and are in remission.
This study tests an oral medication, hetrombopag, to see if it can safely raise platelet counts in people with gynecologic cancers whose platelets drop too low from chemotherapy or other cancer treatments. It may help them continue their cancer therapy without delays or bleeding risks.
This trial studies a pill called herombopag to see if it can prevent low blood platelets caused by chemotherapy (and sometimes radiation) in people with cervical cancer. Low platelets increase the risk of bleeding, and this drug may help keep platelet levels safer so you can continue your cancer treatment.
Hear when a new Chemotherapy Induced Thrombocytopenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.